Sotac Pharmaceuticals logo

Sotac Pharmaceuticals financials: balance sheet, profit and loss, cash flow

NSE: SOTACPharmaceuticals & Biotechnology

Sotac Pharmaceuticals Limited · Face value ₹10 · Listed Apr 2023 · Issue price ₹111
Last close ₹101.30up ₹4.80 (4.97%)

Share price at the NSE close on 28 Oct 2026. Previous close ₹96.50.

28 Oct: open ₹101.25, high ₹101.30, low ₹101.25

52-week range of traded prices to 28 Oct 2026
₹86.00Low, 31 Jul 2026₹139.65High, 28 Nov 2025
Market cap
₹112 Cr
P/E
19.41
P/B
1.90
Dividend yield
0.20%
ROE
10.3%
Debt to equity
0.58
Volume, NSE
2,400100.0% delivered

Sotac Pharmaceuticals' financial statements for the 4 years to Mar 2026, consolidated: the company and its subsidiaries together.

4 years at a glance

₹ crore, years to March.Sotac Pharmaceuticals annual reports

Revenue, net profit and borrowings, ₹ crore

  • Revenue
  • Net profit
  • Borrowings
772.3Mar 231044.3Mar 24978.044Mar 251015.838Mar 26

Operating and net margin, per cent

  • Operating margin
  • Net margin
17.7%3.0%9.4%8.2%14.1%17.7%3.0%4.1%8.3%5.7%Mar 23Mar 24Mar 25Mar 26

The years either side of a change of basis do not compare. From the year to Mar 2026, the company's revenue for that year, ₹101 Cr, differs from its half years added, ₹97 Cr.

Results for the year to Mar 2026

Consolidated: the company and its subsidiaries together. ₹ crore.

From revenue to net profit

  1. Revenue101
  2. Materials and goods−65
  3. Employee costs−3.7
  4. Other expenses−15
  5. Operating profit18
  6. Depreciation−5.4
  7. Other income+0.3
  8. Finance costs−4.1
  9. Profit before tax8.7
  10. Net profit5.8

What the company owns

  • Plant, investments and other assets₹72 Cr
  • Receivables₹33 Cr
  • Inventory₹27 Cr
  • Cash and bank₹1 Cr

What pays for it: net worth and liabilities

  • Net worth₹65 Cr
  • Borrowings₹38 Cr
  • Owed to suppliers₹27 Cr
  • Other liabilities₹4 Cr

Profit and loss

Consolidated, ₹ crore, years to March.Sotac Pharmaceuticals half-yearly results

₹ croreMar 2023Mar 2024Mar 2025Filed 28 MayMar 2026Filed 26 May
Revenue from operations7710497101
70958383
Materials and goods bought57806865
Employee costs4434
Other expenses9121215
Operating profit before depreciation791418
Operating margin9.4%8.2%14.1%17.7%
Materials, % of revenue73.9%76.7%70.4%63.7%
Employee costs, % of revenue5.5%3.8%3.3%3.6%
Other expenses, % of revenue11.3%11.3%12.2%15.0%
Depreciation and amortisation2345
Operating profit after depreciation551012
Other income0040
Finance costs2234
Profit before one-off items and tax34119
One-off items10––
Profit before tax44119
Tax20––
Net profit2486
Net margin3.0%4.1%8.3%5.7%
Tax is left blank for the years to Mar 2025 and Mar 2026: profit before tax less the tax charge stated does not come to the profit after tax the same statement states, so the tax charge is not shown.

Balance sheet

Consolidated, ₹ crore, at 31 March.

₹ croreMar 2025Filed 28 MayMar 2026Filed 26 May
5865
5359
Share capital1111
Reserves4248
Belonging to outside owners of subsidiaries56
4438
5258
1411
Total assets124133
5556
7078
Net debt4236
Borrowings are counted again inside the liabilities due within a year and after a year. No balance sheet is on record for the years to Mar 2023 and Mar 2024, so its lines and the ratios worked from it are blank there.

Cash flow

Consolidated, ₹ crore, years to March.

₹ croreMar 2025Filed 28 MayMar 2026Filed 26 May
−4.316.9
−3.319.0
−20.90.9
Receivables−7.81.2
Inventories−2.3−6.8
Payables−9.98.2
Other working capital−0.8−1.7
Tax paid−0.8−2.1
Capital spending17.06.4
Free cash flow−21.310.5
−13.6−6.9
16.1−10.4
Dividends paid0.00.1
Shares issued0.00.0
Net change in cash−1.9−0.4
Capital spending is part of cash from investing, and dividends paid, shares bought back and shares issued are part of cash from financing. Each is shown as an amount on a line of its own, and the section's other items are in its total only. No cash flow statement is on record for the years to Mar 2023 and Mar 2024.

Per share

Consolidated, ₹ per share, years to March.Sotac Pharmaceuticals dividend history

₹ per shareMar 2024Mar 2025Filed 28 MayMar 2026Filed 26 May
Earnings per share–₹7.26₹5.22
Diluted earnings per share–₹7.26₹5.22
Dividend per share–₹0.10₹0.20
Book value per share–₹48.19₹53.28
Dividend payout–1.4%3.8%
Shareholder yield–0.0%0.1%
Market cap at the year end (₹ crore)134131121

Ratios

Consolidated, years to March.Sotac Pharmaceuticals PE ratio and valuation

RatioMar 2023Mar 2024Mar 2025Filed 28 MayMar 2026Filed 26 May
Revenue growth–34.0%−6.6%–
Operating profit growth–17.5%60.2%–
Net profit growth–87.3%87.5%−28.2%
Earnings per share growth–––−28.1%
––15.1%10.3%
–––−4.8 pts
From the net margin–––−4.7 pts
From asset turnover–––0.1 pts
From borrowing–––−0.2 pts
Return on capital employed––9.6%12.2%
Cash conversion––−54.0%292.5%
Interest cover2.53.23.83.0
Debt to equity––0.750.58
Receivable days––128119
Inventory days––108153
Payable days––101154
Cash conversion cycle, days––135118
Working capital days––174164
Asset turnover––0.780.79
Assets per rupee of net worth––2.332.30
Sales per rupee of plant––2.072.21
Capital spending to depreciation––4.441.18
Revenue growth and operating profit growth are left blank for the year to Mar 2026: between the two periods the company restated its earlier figures, so the two are on different bases and the change is not worked out. No balance sheet is on record for the years to Mar 2023 and Mar 2024, so its lines and the ratios worked from it are blank there.

Growth and returns over 3, 5 and 10 years

Consolidated: the company and its subsidiaries together. Each window ends with the year to Mar 2026.

Return on assets, latest year
4.5%
Cash from operations against operating profit
94.3%
Measure5 years3 years
Profit growth, yearly rate–36.1%
Return on equity, average–12.7%
Return on capital employed, average–10.9%
Operating margin, average12.3%13.3%
Net margin, average5.3%6.0%
Asset turnover, average–0.78
Cash conversion cycle, days, average–127
Interest cover, average3.13.3
Debt to equity, average–0.67

Where the cash came from and went

Consolidated: the company and its subsidiaries together. ₹ crore, added up over each window, which ends with the year to Mar 2026.

₹ croreLatest year
Cash from operations16.9
Cash from investing−6.9
Cash from financing−10.4
Capital spending6.4
Dividends paid0.1
Shares issued for cash0.0
Borrowings raised1.2
Borrowings repaid7.3

Accounting checks

Consolidated, years to March. Published tests of whether reported profit is backed by cash and the balance sheet.

CheckMar 2023Mar 2024Mar 2025Mar 2026
Receivables growth less revenue growthOur threshold 0 percentage points–––−7.79
Inventory growth less cost-of-goods growthOur threshold 0 percentage points–––39.21
Other current assets growth less revenue growthOur threshold 5 per cent of revenue–––2.55
Effective tax ratePublished threshold 17.16 per cent41.789.7016.5927.63
Tax charged less tax paid, % of profitOur threshold 10 percentage points––9.353.71
A threshold marked as ours has no published figure; it is the line we read the check against.